The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida
Authors:
- 6 October 2006
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 84 (12) , 1047-1054
Abstract
The methionine synthase reductase (MTRR) enzyme restores methionine synthase (MTR) enzyme activity and therefore plays an essential role in homocysteine remethylation. In some studies, the 66A>G polymorphism in the MTRR gene was associated with increased neural tube defect (NTD) risk. Using a case-control design, we studied the association between the MTRR 66A>G polymorphism and spina bifida risk in 121 mothers, 109 spina bifida patients, 292 control women, and 234 pediatric controls. Possible interactions between the MTRR 66A>G variant and the MTR 2756A>G polymorphism, the MTHFR 677C>T variant, plasma vitamin B12, and plasma methylmalonic acid (MMA) levels were examined in the 121 mothers and 292 control women. Meta-analyses were conducted to set the results of the case-control study in the context of eligible literature on the relation between the MTRR 66A>G variant and NTD risk. Finally, a transmission disequilibrium test was performed for 82 complete mother–father–child triads to test for preferential transmission of the MTRR risk allele. In our case-control study, the MTRR 66A>G polymorphism had no influence on spina bifida risk in children [odds ratio (OR) 0.6, 95% confidence interval (CI) 0.4–1.1]. The MTRR 66GG genotype increased maternal spina bifida risk by 2.1-fold (OR 2.1, 95% CI 1.3–3.3). This risk became more pronounced in combination with the MTHFR 677TT genotype (OR 4.0, 95% CI 1.3–12.5). Moreover, we demonstrate a possible interaction between the MTRR 66GG genotype and high plasma MMA levels (OR 5.5, 95% CI 2.2–13.5). The meta-analyses demonstrated that the maternal MTRR 66GG genotype was associated with an overall 55% (95% CI 1.04–2.30) increase in NTD risk and that the MTRR 66GG genotype did not increase NTD risk in children (OR 0.96, 95% CI 0.46–2.01). These data show that the MTRR 66GG genotype is a maternal risk factor for spina bifida especially when intracellular vitamin B12 status is low.Keywords
This publication has 33 references indexed in Scilit:
- Impact of Violations and Deviations in Hardy-Weinberg Equilibrium on Postulated Gene-Disease AssociationsAmerican Journal of Epidemiology, 2006
- Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patientsAtherosclerosis, 2004
- Low erythrocyte folate status and polymorphic variation in folate-related genes are associated with risk of neural tube defect pregnancyMolecular Genetics and Metabolism, 2004
- Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defectsMolecular Genetics and Metabolism, 2003
- Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traitsBioinformatics, 2003
- An Examination of Polymorphic Genes and Folate Metabolism in Mothers Affected by a Spina Bifida PregnancyMolecular Genetics and Metabolism, 2001
- Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular diseaseQJM: An International Journal of Medicine, 1997
- Prevention of the First Occurrence of Neural-Tube Defects by Periconceptional Vitamin SupplementationNew England Journal of Medicine, 1992
- Methionine and neural tube closure in cultured rat embryos: Morphological and biochemical analysesTeratology, 1990
- POSSIBLE PREVENTION OF NEURAL-TUBE DEFECTS BY PERICONCEPTIONAL VITAMIN SUPPLEMENTATIONThe Lancet, 1980